Cenedella.de

Patient Advocate since 1977.


Leave a comment

Chris Driessen from ORGANA BRANDS — Celebrate commoditization and the birth of “Big Cannabis”

Celebrate commoditization and the birth of “Big Cannabis”

by Chris Driessen

I now buy legal cannabis by the ton. I negotiate the price of dried, ground marijuana as if it were just another commodity…because it is. Cannabis is simply an amazing agricultural commodity and precious raw material input– dropped into a not-so-complicated equation, designed to produce profit.

Just two years ago I was paying some $2,000 a pound for world class marijuana. Now that price has fallen by two thirds and I pay roughly $600 a pound. This is great news for our purchasing department, but not so much for our wholesale prices. Alas, this was inevitable, it’s simple economics. It makes market expansion all the more critical. If you are not growing, you’re dying, or soon will be. More money in the market invites more competition, which motivates us to innovate, scale and ultimately find efficiencies in our processes.. or be chewed up by the competition.

At Organa Brands, I oversee an entire house of brands that makes everything from cannabis vaporizers to THC tablets, edibles and dabs, and even energy drinks. I expect that before long, our CBD products — many of which have no THC — will be stocked on shelves at convenience stores, gas stations, Costco and Walmart.

Fortunately, that’s where my experience lies. Before entering the world of cannabis, I had spent years as a printer salesman, selling millions of dollars of commercial printers to clients throughout the Rocky Mountain region. The commercial printing business is cutthroat, as any office manager with a decent sized copy machine will attest. The hardware is sold for the narrowest of margins, or even below cost, while the emphasis is put on the consumable commodity, which is the ink.

Seem familiar? If not, what kind of cellphone do you have? You likely got the phone on the cheap or even free, as long as you signed up for the lengthy service contract. Guess where the money is made?

There are purists who shun the idea that if (when) marijuana goes mainstream, it is a disaster. They believe it’s a cave-in to big capital, big corporations, to profiteers and all things sacred of this undoubtedly magical plant. I couldn’t disagree more. If we are to unlock and share the medicinal and wellness properties of cannabis, why not champion the professional distribution of our favorite plant? Why not embrace enterprise resource planning software platforms, hi-tech manufacturing techniques, tighter inventory controls, agricultural efficiencies and crisp profit-and-loss statements?

The best homage we can make to this amazing plant is to produce the finest cannabis oil possible, to place it in attractive, finely-tuned packaging, that is both alluring to adult consumers and childproof, and offer it to consumers nationwide. The greatest contribution I can give to this industry and this amazing plant is to make sure it finds its way into as many lives as possible. We can scale our businesses larger, scrutinize costs and expenses, pour over financial reports and become the solid start-up that transforms into a legacy company that withstands the ups and down of the business world.

I believe we should celebrate national cannabis brands because we are able to incorporate up-and-coming products and place their innovative oils, edibles and medicines into our nationwide distribution network that reaches some 1,200 dispensaries in 10 states (and counting). We should support and encourage each other to become a tribe of companies, a community of cannabis enthusiasts that collectively have the market power of “Big Cannabis”. While that name scares many, it simply means that our industry has “made it.” It means we are here to stay, that we withstood the test of time and government prohibition. We have found a permanent home in the world economy.

When people criticize what they fear is the “homogenization” of marijuana, I can only laugh. Is there any better way to celebrate diversity of brands and up-and-coming entrepreneurial know-how than to offer a launch pad to those superior cannabis products? A launch pad that guarantees their product can be sold from Boston to Berlin, from San Francisco to Sydney?

It has been this same process of consolidation, which is a natural evolution in any maturing industry, that led the O.penVAPE team to look beyond vape pens and incorporate a whole new range of products, and a whole new range of possibilities. That’s why earlier this year we rebranded as Organa Brands — literally a house of brands.

For years, the company where I work was known for its O.penVAPE pens. We sold some 6 million of our cartridges and earned a strong customer following and loyalty with budtenders nationwide. Was that the result of some fortuitous “lucky break” or the natural result of dozens, then hundreds of employees working weekends, staying late and attempting to find a route to success in the highly competitive cannabis industry? I’ll let you answer that one, because I already know.

Our downtown Denver corporate office looks more like a tech startup in Silicon Valley than a mega cannabis conglomerate. We have trendy coffees that self-brew on demand, organic snacks and the requisite office pets and ping pong table. But don’t let the laid back atmosphere or tunes playing on the Sonos fool you. Our office is stocked with brilliant minds ready to go toe-to-toe with Big Tobacco, Big Alcohol and Big Pharma. We relish the opportunity to measure up against other, more mature industries. To do that we must first pass through the inevitable commoditization of our products, work with the compression of profit margins and weather the oncoming storm of consolidation.

I don’t make any medical or health claims about cannabis, but I know that a deep feeling of wellness and peace accompanies the cannabis products we produce. Every day, I receive letters of thanks. If this deep wellspring of consumer support leads to the nation’s first national chain of dispensaries, or million-acre cultivation facility, or a multinational consumer products cannabis company, I say we should all celebrate.


Leave a comment

Leafly Launches German-Language Edition

Leafly German

Leafly.de is a medical cannabis information resource and knowledge portal

BERLIN–(BUSINESS WIRE)–Leafly, the world’s cannabis information resource, has arrived in Germany with the launch of www.Leafly.de, a German-language medical cannabis information resource and knowledge portal. The new German-language version of Leafly capitalizes on the expertise Leafly has cultivated over the past seven years as the world’s most visited cannabis website. As one of Leafly’s most prominent international ventures to date, Leafly.de formalizes Leafly’s commitment to providing reliable, accessible information about cannabis to people in Germany and around the world.

Leafly’s arrival in Germany was celebrated this week at a launch event in Berlin. Medical cannabis patients and representatives from the media joined Leafly’s editorial team to participate in a lively exchange on the topic of medical cannabis. Leafly’s inaugural German-language editorial team includes a range of healthcare experts, including science journalists, researchers, and a doctor. The launch of Leafly.de follows Leafly’s appearance at Berlin’s annual Hanfparade last year. Hanfparade is the largest pro-cannabis and hemp event in Germany that has taken place every year since 1997.

Leafly is the world’s leading cannabis website and mobile application, generating more than 12 million unique visits per month and more than 60 million page views. Approximately 70 percent of Leafly’s traffic comes from the United States and 30 percent originates from international destinations, including Australia, Canada, France, Germany, Spain, South Africa, and the United Kingdom. With the launch of Leafly.de, Leafly is now available in English, Spanish, French, and German.

Leafly.de initially will focus on several subject areas of immediate concern to medical cannabis patients and their healthcare providers. Visitors to the site can learn more about Germany’s recent medical cannabis reforms, how those changes affect them, and how they can become medical cannabis patients. News and analysis regarding medical cannabis laws and the supply of licensed cannabis-derived medicines will also be covered. In addition, Leafly.de will serve as a guide for doctors, pharmacists, and other medical professionals to learn more about the medical use of cannabis for conditions such as chronic pain.

Leafly.de taps into Leafly’s global coverage of cannabis science, medicine, and patient trends. Visitors will find the latest scientific research, patient surveys, and breaking news. The site also features a comprehensive cannabis dictionary featuring information from the anatomy of the cannabis plant to breaking policy news in Germany. The depth of Leafly’s expertise is why millions of people around the world visit Leafly every month for cannabis news and information.

Visit http://www.Leafly.de for more information.

About Leafly

As the world’s largest cannabis information resource, Leafly’s mission is to help patients and consumers make informed choices about cannabis and to empower cannabis businesses to attract and retain loyal customers through advertising and technology services. Learn more at http://www.leafly.com or download the five-star rated Leafly mobile app through Apple’s App Store or Google Play.

Original press release: http://www.businesswire.com/news/home/20170512005681/en/Leafly-Launches-German-Language-Edition

 


2 Comments

Germany: Cultivation License, tender information

Germany-Bonn: medical equipment, pharmaceuticals and personal care products

http://ted.europa.eu/udl?uri=TED:NOTICE:131987-2017:TEXT:DE:HTML&src=0#id1042115-III.

2017 / S 070-131987

contract notice

Supplies

Directive 2014/24 / EU

Section I: Contracting authorities

I.1)Name and addresses

Federal Institute for Drugs and Medical Devices (BfArM)
Kurt-Georg-Kiesinger-Allee 3
Bonn
53175
Germany
Contact: Bundesinstitut für Arzneimittel und Medizinprodukte, Frau Stefanie Vogt
Phone: +49 228-2074124
E-Mail: Z122@bfarm.de
Fax : +49 228-2074352
NUTS Code: DEA22Internet address (es):Main address: http://www.bfarm.de

I.2)Common procurement strategy

I.3) Address from whichfurther information can be obtained:

The order documents are available free of charge for full and complete direct access at: https://www.evergabe-online.de/tenderdetails.html?id=156533
Further information can be obtained from the above-mentioned contact point (s)
Tenders or requests to participate must be submitted to the above mentioned contact point (s)

I.4)Type of the contracting authority

Ministry or other central or federal authority, including regional or local subdivisions

I.5)Main activity (s)

health

Section II: Subject

II.1)Scope of procurement

II.1.1) Titleattributed to the contract:

Cultivation, processing, storage, packaging and delivery of cannabis for medical purposes.

Reference number of the contract notice: 2281-1713

II.1.2) Mainterms of the sale or purchase:

33000000

II.1.3)Type of contract

Supplies

II.1.4)Short description:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

II.1.5)Estimated total value

II.1.6)Information about lots

Division of the contract into lots: yes
Offers are possible for all lots
Maximum number of lots to be awarded to a contracting authority: 7
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany

Lot No: 1

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 1): delivery period 2019 to 2022, delivery volume approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum 40 points) per 50 kg of delivery (whether in the context of one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a delivery quantity of at least 50 kg per reference over the last three years (whether in the case of a single order or several contracts) Points (maximum score 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

D) If fewer than 10 applicants receive a score of 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

Lot No: 2

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 1): delivery period 2019 to 2022, delivery volume approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum 40 points) per 50 kg of delivery (whether in the context of one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a minimum quantity of 50 kg per reference for the last three years (whether in the case of a single order or several contracts): the applicant receives 5 points per 50 kg delivery (A maximum of 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total quantity delivered in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

Lot No: 3

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 1): delivery period 2019 to 2022, delivery volume approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum 40 points) per 50 kg of delivery (whether in the context of one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a minimum quantity of 50 kg per reference over the last three years (whether in the context of one or more contracts): The applicant shall be supplied per 50 kg of delivery 5 points (maximum score 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

D) If fewer than 10 applicants receive a score of 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

Lot No: 4

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 1): delivery period 2020 to 2022, delivery volume approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum of 40 points) for each 50 kg of delivery (whether for one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a delivery quantity of at least 50 kg per reference over the last three years (whether in the case of a single order or several contracts) Points (maximum score 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

D) If fewer than 10 applicants receive a score of 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

Lot No: 5

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 1): delivery period 2020 to 2022, delivery volume approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum of 40 points) for each 50 kg of delivery (whether for one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a delivery quantity of at least 50 kg per reference over the last three years (whether in the case of a single order or several contracts) Points (maximum score 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

D) If fewer than 10 applicants receive a score of 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

Lot No: 6

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 1): delivery period 2021 to 2022, delivery quantity approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum 40 points) per 50 kg of delivery (whether in the context of one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a delivery quantity of at least 50 kg per reference over the last three years (whether in the case of a single order or several contracts) Points (maximum score 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

D) If fewer than 10 applicants receive a score of 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

Lot No: 7

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 2): delivery period 2019 to 2022, delivery volume approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum of 40 points) for each 50 kg of delivery (whether for one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a delivery quantity of at least 50 kg per reference over the last three years (whether in the case of a single order or several contracts) Points (maximum score 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

D) If fewer than 10 applicants receive a score of 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

Lot No: 8

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 2): delivery period 2020 to 2022, delivery volume approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum of 40 points) for each 50 kg of delivery (whether for one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a delivery quantity of at least 50 kg per reference over the last three years (whether in the case of a single order or several contracts) Points (maximum score 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

D) If fewer than 10 applicants receive a score of 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

Lot No: 9

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 3): delivery period 2019 to 2022, delivery volume approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum 40 points) per 50 kg of delivery (whether in the context of one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a delivery quantity of at least 50 kg per reference over the last three years (whether in the case of a single order or several contracts) Points (maximum score 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

D) If fewer than 10 applicants receive a score of 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information
II.2)Description

II.2.1)Title attributed to the contract:

Cultivation, further processing, storage, packaging and delivery of cannabis for medical purposes in a secure inhouse plantation in Germany.

Lot No: 10

II.2.2)Additional CPV code (s)

03117120

II.2.3)Place of performance

NUTS code: DEA22

II.2.4)Description of the sourcing:

Cultivation, processing, storage, packaging and delivery of cannabis (type 3): delivery period 2021 to 2022, delivery quantity approx. 200 kg per year.

II.2.5)Award criteria

The price is not the only supplementary criterion; All criteria are listed in the procurement documents only
II.2.6)Estimated value

II.2.7)Duration of the contract or framework agreement or of the dynamic purchasing system

Duration in months:
This contract can be extended: no

II.2.9)Indication about the number of operators who will be invited to tender or to participate

Planned number of candidates: 10
Objective criteria for selecting the limited number of applicants:

(A) references to earlier contracts awarded by the applicant for the cultivation, processing and delivery of cannabis for medical purposes with a delivery quantity of at least 50 kg per reference for the last 3 years. A reference to an order for the cultivation, processing and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to this body in accordance with Article 23 of the 1961 Unified Agreement on Narcotic Drugs A variety of different performance receivers have been delivered and the total delivery quantity has amounted to at least 50 kg. The applicant will receive 10 points (maximum 40 points) per 50 kg of delivery (whether in the context of one or more orders).

(B) references to the cultivation, processing and supply of medicinal plants (without cannabis) with a minimum quantity of 50 kg per reference over the last three years (whether in the context of one or more contracts): The applicant shall be supplied per 50 kg of delivery 5 points (maximum score 20 points).

C) If more than 10 applicants receive a score of more than 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

D) If fewer than 10 applicants receive a score of 60, the selection is based on the highest total delivery quantity in the last three years according to lit. A), according to lit. b).

II.2.10)Information about variants / alternative offers

Variants / alternative offers are permitted: no

II.2.11) Informationon options

Options: no
II.2.12)Information about electronic catalogs

II.2.1)Information about European Union funds

The contract is linked to a project and / or program financed by the EU: no
II.2.1)Additional information

Section III: Legal, economic, financial and technical information

III.1)Conditions for participation

III.1.1)Empowerment in professional or professional capacity, including requirements relating to the professional or trade registers

Listing and brief description of the conditions:

The tenderer’s declaration of entry in a professional or trade register or other proof of the professional qualification required in the State in which the applicant is established.

The client reserves the right to submit the following documents within the framework of the appraisal of the participation requests to a separate request:

– Local business register,

– a certificate from the competent social security authorities that social security contributions are paid in accordance with the regulations,

– the certificate of the competent professional association that the tenderer is a member there and who is contributing,

– Tax exemption certificate issued by the tax office,

– Declaration on the grounds of exclusion pursuant to §§ 123, 124 GWB.

III.1.2)Economic and financial capacity

List and brief description of the suitability criteria:

– the total turnover of the applicant in the last three financial years, if any.

– information on the applicant’s turnover in the area of ​​the cultivation, processing and delivery of cannabis for medical purposes, where available.

– an indication of the applicant’s turnover in the area of ​​the cultivation, processing and supply of medicinal plants during the last three financial years, where available.

– an indication of the existence of a professional or occupational liability insurance amounting to EUR 5 million (twice a year maximized) or the tenderer’s assurance to conclude such insurance in the case of the subdivision.

– submit the candidates’ annual accounts, if their publication is legally required by the applicant.

– indication that the financing of the contract is to be secured (financing by equity, shareholder loans, loans from a credit institution or similar), as well as the insurer’s insurance A corresponding commitment from the financing credit institution.

III.1.3)Technical capacity and professional capacity

List and brief description of the suitability criteria:

Information on the tenderer ‘s previous contracts for the cultivation, processing and delivery of medical cannabis in the last three years, if any (list showing the contract value, the delivery quantity, the delivery period and the recipient of the service and, where available, Country competent authority in accordance with Article 23 of the “Unity Convention 1961 on Narcotics” concluded in New York on 30 March 1961).

– information on the tenderer’s references to contracts for the cultivation, processing and delivery of medicinal plants carried out in the past three years, where available (list showing the contract value, the delivery volume, the delivery period and the beneficiary).

– indication of the technical personnel to be used by the tenderer in connection with the service.

– information on the equipment, equipment and technical equipment of the contractors to carry out the contract.

Minimum standards required:

At least one reference for the purpose of cultivation, processing and delivery of medicinal cannabis (minimum quantity of 50 kg) or a contract for the cultivation, processing and supply of medicinal plants (minimum 50 kg) for the last three years. A reference to a contract for the planting and delivery of medical cannabis shall also apply if, with the consent of the competent authority in the country concerned, the tenderer submits directly to a variety of different beneficiaries, in accordance with Article 23 of the “Unified Convention on Narcotic Drugs” And the total quantity delivered is at least 50 kg. As a reference about an order to cultivate,

III.1.5)Information about reserved contracts
III.2)Conditions relating to the contract

III.2.2)Conditions relating to the performance of the contract:

Permission according to § 3 Drugs Act.

Permission according to § 13 Arzneimittelgesetz.

III.2.3)Personnel responsible for execution of the contract

Obligation to indicate the names and professional qualifications of the persons responsible for the execution of the contract

Section IV: Procedure

IV.1)Description

IV.1.1) Type ofprocedure

negotiated procedure
IV.1.3)Information about a framework agreement or a dynamic purchasing system (DPS)

IV.1.4) Informationabout reduction of the number of operators or solutions to be taken during the negotiation or dialogue

The succession of the procedure in successive stages in order to gradually reduce the number of solutions to be discussed and / or the tenders to be negotiated
IV.1.5)Information about a negotiated procedure
IV.1.6)Information about electronic auction

IV.1.8) Informationabout the Procurement Agreement (GPA)

The contract is covered by the Procurement Agreement: no
IV.2)Administrative informationIV.3)
IV.2.1)Previous publication concerning this procedure

IV.2.2)Time-limit for receipt of tenders or requests to participate

Day: 05/06/2017
Local Time: 12:00

IV.2.3)Time-limit for receipt of tenders or requests to participate:

Day: 28/06/2017

IV.2.4)Language (s) in which tenders or requests to participate may be drawn up:

German

IV.2.6)Minimum time frame during which the tenderer must maintain the tender

Duration in months: 6 (from the date of receipt of tenders)
IV.2.7)Conditions for opening tenders

Section VI: Additional information

VI.1)Information about a return of the contract

This is a recurring job: yes
Estimated timing for further notices:

02/01/2021.

VI.2)Information about electronic work processes

No. VI.3)Additional information:

Details of the invitation to tender and of the documents to be submitted can be found in the tender form “Procurement procedure for the cultivation, processing, storage, packaging and delivery of cannabis for medical purposes, here: Invitation to submit applications for participation”, which forms part of the tender documents.

This procurement procedure will be carried out electronically on the website of the eVergabe platform ( www.evergabe-online.de ).

Please note that the free download of the tender documents is only for a first view. In order to participate in the tender, you must apply for participation. Only if you apply for the tender, you will be actively informed about any changes to the tender documents and will be able to ask questions about the tender or receive the answers.

Any legal or professional questions concerning the award procedure or the tender documents must be addressed to the eVergabe platform.

VI.4)Procedures for appeal / review

VI.4.1) Bodyresponsible for appeal procedures

Awarding Office of the
Confederation Villemombler Straße 76
Bonn
53123
Germany
VI.4.2)Body responsible for appeal procedures

VI.4.3)Lodging of appeals

Precise information on the time limits for lodging appeals:

Section 160 GWB

(1) The awarding authority shall initiate a review procedure only upon request.

2. Any undertaking which is interested in the public contract or the concession and who asserts an infringement in its rights pursuant to Article 97 (6) by not observing public procurement rules shall have the right to submit applications. It must be shown that the alleged infringement of the public procurement rules has caused or is likely to result in damage to the company.

(3) The application is inadmissible in so far as:

1. the applicant has recognized the alleged infringement of public procurement rules before submitting the request for review and has not complained to the contracting authority within a period of ten calendar days; The expiry of the time limit pursuant to Section 134 (2) shall remain unaffected,

2. Infringements of public procurement rules which are discernible on the basis of the notice shall not be complained to the contracting authority not later than the expiry of the period set out in the notice of invitation to tender,

3. Infringements of the public procurement rules, which are only recognizable in the tender documents, are not complained against the contracting authority at the latest until the expiry of the deadline for the application or tender,

4. have passed more than 15 calendar days after receipt of the notice of the contracting authority not to remedy a complaint.

VI.4.4)Service from which information about the lodging of appeals may be obtained

Awarding Office of the
Confederation Villemombler Straße 76
Bonn
53123
Germany

VI.5)Date of dispatch of this notice:

04/04/2017


Leave a comment

Legalize It, a Zurich-based group, has launched a campaign to legally regulate cannabis across Switzerland

Could Switzerland Become the First European Country to Legally Regulate Cannabis?

Nine years after a Swiss referendum failed to gain public approval for cannabis legalisation, a campaign group has reignited the movement for reform.

Legalize It, a Zurich-based group, has launched a campaign to legally regulate cannabis across Switzerland. The objectives of the initiative, Legalize It describes, are three-fold: to allow adults the “freedom and right to consume cannabis”, to prevent those who seek cannabis from having to purchase from the “black market”, and to ensure increased investment into drug use prevention, related research, and social security. The funds for such investment, the group says, will be acquired from the taxation of cannabis sales, and savings on law enforcement expenditure.

The campaign comes in the form of a federal popular initiative, a legislative instrument by which Swiss citizens can suggest changes in the law. If the proposal garners 100,000 valid signatures from Swiss citizens, it will be put forward for debate by the Federal Council, the country’s highest executive authority, and the Federal Assembly, the highest legislative authority.

The Federal Palace of Switzerland. Source: Wikimedia Commons

The cultivation, sale, and use of cannabis are outlawed in Switzerland in almost all cases, however punishment for minor possession is relatively light. Under the current law, an adult found to be in possession of up to 10 grams of cannabis will be fined 100 Swiss francs (£78), and will not be criminally prosecuted. In 2015, there were a total of 18,366 such fines across Switzerland.

Around three percent of adult Swiss residents use cannabis monthly, and almost 40 per cent of adults claim to have used it at least once in their life, according to Addiction Monitoring in Switzerland.

An attempt to legally regulate cannabis was resoundingly opposed by the public in a 2008 referendum, in which 63 per cent of voters opposed the measure. However, the public’s view on the subject has changed over the past decade, according to Nino Forrer, spokesperson for Legalise It.

“Many other countries have legalised or decriminalised cannabis in some form since 2008 and the results are good […] Based on this new data, the Swiss people will see more benefits than harms in legalising cannabis, I’m sure”, Forrer told TalkingDrugs.

“There has not been a massive rise in cannabis consumption among the youth [in places that have legalised cannabis], no surge in traffic accidents, no massive increased health costs. Instead, many jurisdictions have put the extra money from cannabis taxes into public healthcare, infrastructure, and schools in order to improve the standard of living for their people.”

A legal cannabis crow in Colorado. Source: Brett Levin

For example, in 2016, the US state of Colorado collected over $150 million in cannabis sale taxes, of which around $50 million was directed to school projects. Similarly, Legalize Itclaims that taxing the drug could raise 100 million Swiss francs (£78 million) each year, based on their estimates of consumption rates.

Forrer believes that the success of foreign initiatives, such as that in Colorado, may be enough for the Swiss authorities and public to support Legalize It’s new campaign – but only if the message can be effectively be delivered.

“We have had very good responses so far! Many people in Switzerland were waiting for this initiative, so they are very happy that we have started it”, Forrer told us.

“Now, we will try to inform the public as much as possible in order to gather a strong activist base all over the country. Mass media affects our perception of cannabis to a large extent, so good press is needed in order to win over the minds of Swiss people”.

If this initiative proves successful, Switzerland could become the first country in Europe to introduce a legally regulated cannabis market.

Avinash Tharoor is the Editor of TalkingDrugs. He tweets at @AvinashTharoor


Leave a comment

Why is Big Pharma fighting Medical Marijuana so hard? A new report published in Health Affairs found that if all states had legalized medical cannabis in 2014, Medicaid could have saved $1 billion in spending on prescriptions…could be one of the reasons.

If all states had had a medical marijuana law in 2014, we estimated that total savings for fee-for-service Medicaid could have been $1.01 billion. 

I write about retail and cannabis.

A new report published in Health Affairs found that if all states had legalized medical marijuana in 2014, Medicaid could have saved $1 billion in spending on prescriptions.

The study by Ashley C. Bradford and W. David Bradford examined whether states with medical marijuana laws saw changes for prescription drugs among Medicare Part D enrollees. Their analysis covered data between 2007 to 2014 and found that patients did indeed substitute medical marijuana for FDA-approved prescription drugs in these states.

“Total estimated Medicaid savings associated with these laws ranged from $260.8 million in 2007 to $475.8 million in 2014,” the study states. Granted this is only 2% of the total Medicaid drug spending for 2014, which was $23.9 billion, but it is still substantial savings. The Bradfords estimate that if all states had legalized medical marijuana in 2014, “The national savings for fee-for-service Medicaid would have been approximately $1.01 billion.” This works out to an average per state savings of $19.825 million a year.

However, only 26% of Medicaid customers are enrolled in the fee-for-service program. The study notes that if they applied their analysis equally to Medicaid managed care, then the savings could jump to a whopping $3.89 billion. Again, this is only if all states legalized medical marijuana.

Granted the savings are mostly enjoyed by private insurers that run the plans, but the Bradfords suggest that state governments could reduce their payments to the insurers as prescription drug costs fall.

The study only looked at conditions that could be treated with medical marijuana and the prescription drugs that would be affected. This included anxiety, depression, glaucoma, nausea, pain, psychosis, seizures, sleep disorders and spasticity. According to the study, “the differences ranged from a 42% reduction for prescriptions used to treat nausea to a 15% reduction for spasticity.” The Bradfords also found a 13% decline in depression drug prescriptions, a 12% drop in psychosis drug prescriptions and an 11% slide in pain drugs. There was no significant drop in drugs used for anxiety, glaucoma or sleep disorders.

The Bradfords noted that their study was challenged by the fact that states keep changing their medical marijuana laws and expanding approved conditions. Furthermore, they only had data available from fee-for-service Medicaid prescriptions. Managed care patient data was inconsistent. Thus, their findings are really lower than what the true savings could really be, suggesting it could be in the billions.


Leave a comment

Import & Export of Medicinal Cannabis Products…to and from Canada.

Blue Diamond Ventures, Inc. a Colorado Corporation ( OTC PINK : BLDV ) today announces that the company has entered into a Joint Development Agreement with Alternative Medical Solutions Inc., to import & export Targeted Medicinal Cannabis Products and Advanced Cannabis Technologies, to and from Canada.

The recent CannaTech Conference in Israel provided the forum to secure the initial agreements required to pursue this effort. Blue Diamond Ventures is not alone; Jeffrey Friedland, noted author and cannabis thought leader, has announced that CannRX is taking a similar approach by partnering to bring Israeli Technologies into the U.S. and other countries. https://israel-cannabis.com/2017/03/22/cannrx-icanisrael-ican-sleep/

Alternative Medical Solutions (AMS) is in the final stage to gain a full license to grow, market and sell medicinal cannabis products via Health Canada. BLDV has been working with AMS over the last year to finalize funding for its Fifty (50) thousand square foot cultivation facility. “There has been recognition, by the Canadian Government, for the need to allow import and export in this industry,” says Joshua B. Alper, CEO of BLDV. “This new effort will ensure that AMS, when licensed, will be a Global Project, with their products being available worldwide and with access to the ingredients and technology that will continue to make AMS a leader in the Canadian market.”

“We are excited to launch this effort with BLDV,” said Joseph Groleau, VP Business Development for AMS. “With the specialized products and technologies coming into Canada from Israel, and access to global markets with our finished products, we see this as a separate profit center that could even outgrow our efforts in cultivation.”

Canada will be the home to the new joint venture, and the first market focus will be to bring Israeli Cannabis products and technology to Canada. “AMS is the perfect partner for this project,” said Joshua B. Alper, CEO of Blue Diamond Ventures, Inc. “They have a great team at AMS that has been challenged by the ever-shifting landscape of compliance and financial requirements, this project can create significant revenue even prior to AMS receiving the cultivation and manufacturing licenses from Health Canada.” BLDV senior project manager, Jonathan B. Alper, who is fluent in Hebrew and has been involved in import and export of products from Israel, to Canada, and the U.S. for over 25 years, will manage the effort in cooperation with a team of license and compliance experts in Canada.

In other news:

BLDV has filed its Annual Report on the OTC Markets and has recently secured employment contracts with all key personnel for common stock, without the need to raise authorized common stock levels, or issue special warrants, options and/or preferred stock.

About BLDV:

Blue Diamond Ventures, Inc. seeks to partner with individuals and companies that share a common synergy, mission, and vision to enable products/services that are produced, delivered and consumed utilizing fewer natural resources, providing a sustainable alternative to traditional products on the market today. As a diversified customer centric Management / Holding Company; Blue Diamond Ventures, Inc. seeks opportunities in various markets and is driven by critical thinking and the scientific method.

About AMS:

Alternative Medical Solutions (“AMS”) is in the process of becoming a Licensed Producer of Medical Marijuana in Canada and is led by a highly passionate team dedicated to being at the forefront of the growing Medical Marijuana industry.

Safe Harbor:

This press release contains forward-looking statements. Such forward-looking statements are subject to several risks, assumptions, and uncertainties that could cause the Company’s actual results to differ materially from those projected in such statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly revise any forward-looking statements.


Leave a comment

The Cannabis Agency is a specialist area in the Department of Admission 4 (Special Therapies and Traditional Medicines) in the BfArM

http://www.bfarm.de/DE/Bundesopiumstelle/Cannabis/Cannabisagentur/_node.html

The Act on the Amendment of Drugs and Other Provisions, which entered into force on 10 March 2017, has expanded the scope for the prescription of cannabis medicines. The Act provides for the establishment of a government agency, the so-called cannabis agency, in accordance with the provisions of the United Nations Unity Treaty of 1961 on United Nations drugs. This will control and control the cultivation of cannabis for medical purposes in Germany.

Until cannabis is available for medical purposes from German cultivation, the demand is still covered by imports, for which the cannabis agency is not responsible (further information – see Bundesopiumstelle ).

The Cannabis Agency is a specialist area in the Department of Admission 4 (Special Therapies and Traditional Medicines) in the BfArM . It controls cultivation, harvesting, processing, quality testing, storage, packaging as well as delivery to wholesalers and pharmacists or manufacturers. The cannabis agency will take possession of the cannabis for medical purposes after the harvest.

The harvest is not transported to the BfArM , it is not stored there, nor is it redistributed from there. These steps will be located spatially at the respective construction companies or other commissioned companies.

The cultivation is therefore not carried out in the BfArM or by the BfArM itself, but by companies selected in a Europe-wide tender procedure and commissioned by the cannabis agency. The procedure takes into account all drug and narcotic drug requirements.

The tender procedure has now been published in the Official Journal of the European Union.
The following link leads to the tender documents: Supplement to the Official Journal of the European Union

Communication in connection with the tendering procedure takes place exclusively through the electronic award platform.

Cannabis will be grown exclusively for medical purposes. It is therefore a medicine. Only cannabis grown according to the guidelines of the Good Agricultural and Collection Practice (GACP ) will be used, which corresponds to the specifications of the Monograph “Cannabis Blossoms” ( DAB ) and the Requirements of the other relevant monographs and guidelines. This ensures the availability of cannabis for medical purposes in reproducible quality in accordance with drug laws. The cannabis for medical purposes is also subject to the provisions of the law on narcotic drugs.

The cannabis agency will set a manufacturer’s fee and sell the cannabis to cannabis drug manufacturers, wholesalers or pharmacies. The cannabis agency is not allowed to make any profits or surpluses. In the case of pricing, however, the personnel and material costs incurred by the BfArM are taken into account. However, the cannabis agency has no influence on the actual sales price in the pharmacy. The distribution channels of manufacturers and dealers will comply with the legal regulations and are thus identical with the regulations for the distribution of other drugs containing narcotic drugs.

Here you can find information about the cannabis agency and the cannabis cultivation of cannabis controlled by the cannabis agency for medical purposes:

Why must a so-called cannabis agency be established?
Where is the cannabis agency located?
What are the tasks of the cannabis agency?
What are the foundations of the tendering procedure?
How do I participate in the tender procedure?
Can you ask questions about the tender procedure?
How is the quality of the cannabis cultured in Germany to be used in the future?